|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
<i>TERT</i> promoter mutations are selectively observed among 1p/19q-codeleted oligodendrogliomas and isocitrate dehydrogenase gene- <i>(IDH-)</i> wildtype glioblastoma (GBM).
|
29693015 |
2018 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
36 (57%) had oligodendroglioma and 27 astrocytoma.IDH-1 mutation was present in 53 (84%).
|
30292978 |
2018 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Oligodendrogliomas with a mutant IDH1 had noteworthy enhanced expression of enzymes controlling aerobic glycolysis and detoxification, and anti-apoptosis proteins.
|
21898821 |
2011 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IDH1 mutations were co-present with TP53 mutations in 63% of low-grade diffuse astrocytomas and with loss of heterozygosity 1p/19q in 64% of oligodendrogliomas; they were rare in pilocytic astrocytomas (10%) and primary glioblastomas (5%) and absent in ependymomas.
|
19246647 |
2009 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IDH1 or IDH2 mutations were frequently in oligodendrogliomas (67%), anaplastic astrocytomas (62%), anaplastic oligoastrocytomas (75%), anaplastic oligodendrogliomas (50%), secondary glioblastomas (67%), gangliogliomas (38%), and anaplastic gangliogliomas (60%).
|
19765000 |
2009 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IDH1 mutations were associated with prolonged survival from the diagnosis of PD in oligoastrocytomas (OA II)/oligodendrogliomas (O II) and with overall survival (OS) in all tumors.
|
21558404 |
2011 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IDH1 mutations are the earliest detectable genetic alteration in precursor low-grade diffuse astrocytomas and in oligodendrogliomas, indicating that these tumors are derived from neural precursor cells that differ from those of primary glioblastomas.
|
23209033 |
2013 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IDH1 mutation is prognostic for diffuse astrocytoma but not low-grade oligodendrogliomas in patients not treated with early radiotherapy.
|
26243269 |
2015 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IDH1-R132H and 1p19q loss were found only in 12 out of the 13 oligodendrogliomas (P<0.0001).
|
27389560 |
2016 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IDH1(R132) mutation was most frequent in oligodendrogliomas (57/62, 91.9%), with IDH1(R132H) mutation as the most frequent mutation form.
|
27780605 |
2016 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A better prognosis was significantly associated with combined IDH1 mutation and MGMT methylation status (both positive vs both negative, HR 0.079 [95% CI 0.008-0.579], p=0.012), as well as histology (OG vs DA and OA, HR 0.158 [95% CI 0.022-0.674], p=0.011) and tumor size (<6 cm vs ≥6 cm, HR 0.120 [95% CI 0.017-0.595], p=0.008).
|
26276726 |
2015 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A c.515G>T (p.R172M) mutation of the IDH2 gene was only identified in a grade II oligodendroglioma patient which was wild-type for IDH1.
|
21643842 |
2011 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A total of 135 cases consisted of 38 IDH-mutant [17 astrocytoma (AC), 13 oligodendroglioma (OD) and eight glioblastoma (GBM)], 87 IDH-wildtype (six AC, three OD and 78 GBM), and 10 diffuse midline glioma, H3K27M-mutant.
|
30710203 |
2019 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A total of 221 somatic IDH1 mutations were detected and the highest frequencies occurred in diffuse astrocytomas (68%), oligodendrogliomas (69%), oligoastrocytomas (78%) and secondary glioblastomas (88%).
|
18985363 |
2008 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
After adjustment for IDH mutation, sex, and age, CDKN2A deletion was strongly associated with poorer overall survival in astrocytomas but not in oligodendrogliomas or oligoastrocytomas.
|
25853694 |
2015 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
ATRX retention in IDH1/2 mutant tumors was strongly associated with LOH 1p/19q and oligodendroglioma histology (p < 0.0001).
|
27311324 |
2016 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Both 1p19q codeletion and IDH-1 mutation predict outcome of patients with both oligodendroglioma and AO.
|
22396073 |
2012 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Causal genetic changes in oligodendrogliomas (OD) with 1p/19q co-deletion include mutations in IDH1, IDH2, CIC, FUBP1, TERT promoter and NOTCH1.
|
25694352 |
2015 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Diffuse gliomas can be separated in astrocytoma and oligodendroglioma based on IDH1/2, ATRX, and TP53 mutational status.
|
31714292 |
2020 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Distinct spectral profiles were observed for lesions with IDH-mutated genotypes, between astrocytoma and oligodendroglioma histologies, as well as for tumors that had undergone MP.
|
28327577 |
2017 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Early contrast enhancement that develops during the first 6 months after chemoradiotherapy is typically due to PsP and occurs primarily in OG and MOA that are 1p/19q intact and IDH WT.
|
27704386 |
2016 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, identification of a common IDH1 mutation in enchondroma and oligodendroglioma-matched pair specimens supports the hypothesis that IDH1/2 mosaicism initiates tumorigenesis.
|
29224049 |
2018 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Gliomas were assigned to one of the three molecular groups: Group O (IDH-mutant, 1p/19q co-deleted oligodendrogliomas, n = 95), Group A (IDH-mutant, ATRX inactivated astrocytomas, n = 175) and Group G (IDH wild-type, GBM-like, n = 46).
|
30536195 |
2019 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Here we profile 4,347 single cells from six IDH1 or IDH2 mutant human oligodendrogliomas by RNA sequencing (RNA-seq) and reconstruct their developmental programs from genome-wide expression signatures.
|
27806376 |
2016 |
|
Well Differentiated Oligodendroglioma
|
0.400 |
Biomarker
|
disease |
CTD_human |
IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
|
20160062 |
2010 |